Elevar Lirafugratinib Faces Sept 27 PDUFA

Update September 4, 2026: Corrected a ticker error. This article originally identified Elevar as “NASDAQ: ELEV” trading “at $0.365 per share.” ELEV is the ticker for Elevation Oncology, a separate company that was acquired by Concentra Biosciences and delisted on July 23, 2025. Elevar Therapeutics is a majority-owned subsidiary of HLB Co., Ltd. (KOSDAQ: 028300.KQ) and is not US-listed — there is no direct US ticker to trade lirafugratinib. Exposure is only available through the parent HLB on the Korean exchange. The September 27 PDUFA itself is unchanged.

The FDA set a September 27 PDUFA date for lirafugratinib, Elevar Therapeutics’ selective oral FGFR2 inhibitor for previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma. Elevar is a majority-owned subsidiary of HLB Co., Ltd., which trades on the Korean exchange (KOSDAQ: 028300.KQ); Elevar itself is not US-listed, so there is no direct US ticker to trade this binary.

The NDA is supported by data from the Phase 1/2 ReFocus trial (NCT04526106), which showed a confirmed objective response rate of 46.5% in patients with the proposed indication. The FDA granted Priority Review, Breakthrough Therapy, and Orphan Drug designations. The agency is not currently planning an advisory committee meeting.

Lirafugratinib, also known as RLY-4008, was licensed from Relay Therapeutics, which developed the drug using its switch-control kinase inhibitor platform. Unlike older pan-FGFR inhibitors that hit FGFR1, 2, 3, and 4 broadly, lirafugratinib selectively targets FGFR2, reducing off-target toxicities like hyperphosphatemia and nail toxicity that limit the older drugs’ dosing.

If approved, lirafugratinib would enter a competitive but narrow market. Incyte’s Pemazyre (pemigatinib) and Taiho’s Lytgobi (futibatinib) are both already approved for the same FGFR2-driven cholangiocarcinoma population after prior chemotherapy. Both are pan-FGFR inhibitors. The selective FGFR2 targeting is lirafugratinib’s differentiator, though it enters the market third with no head-to-head data against the established options.

Cholangiocarcinoma, or bile duct cancer, is rare and aggressive. Roughly 8,000 to 13,000 new cases are diagnosed annually in the US, and FGFR2 fusions or rearrangements appear in 10-15% of intrahepatic cases. The patient population is small, which is why Orphan Drug designation applies.

For Elevar, this is the second FDA decision in 2026. The company’s other lead asset, rivoceranib plus camrelizumab for first-line liver cancer, received a third Complete Response Letter from the FDA earlier in July. That rejection leaves lirafugratinib as the company’s near-term survival bet. A non-US-listed subsidiary of HLB with one pending FDA decision and a rejected combination therapy has limited financial runway. Investors approaching this PDUFA should understand the binary dynamics of trading FDA catalysts: HLB’s stock will move sharply in either direction on September 27.

The risk is clear. Elevar enters the FGFR2 CCA market third, behind two approved competitors, with no randomized trial data and no head-to-head comparison. The ReFocus trial is a single-arm Phase 1/2 study, meaning the 46.5% ORR is measured against historical benchmarks, not a concurrent control. If the FDA demands a randomized trial before approval, HLB has nowhere to go but down.

What to watch: the September 27 decision. There is no advisory committee scheduled, which typically signals a cleaner review, but Elevar’s recent CRL on rivoceranib shows the FDA is willing to reject this company’s filings.